Third Rock Ventures has led a series A round for Abata Therapeutics, launched by the firm to commercialise research from Harvard, MIT, Johns Hopkins, NIH and UZH.
Abata Therapeutics, a US-based cell therapy developer focused on autoimmune and inflammatory diseases, has launched with $95m in series A financing led by Third Rock Ventures to advance research from multiple institutions.
Gene and cell therapy developer ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital and the JDRF T1D Fund participated in the round, which followed an undisclosed amount of seed capital supplied by Third Rock and ElevateBio at an unspecified date.
Abata Therapeutics is working on translating the…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
